Unlike most prior work, which has focused primarily on surrogate solute kinetics or broad quality of life domains, we paired these quantitative clearance data with detailed inflammatory, nutritional, and lipid biomarker trajectories, confirming that better solute removal does not come at the expense of albumin loss or malnutrition [14,15,16,17]. The gene discussed is ALB; the disease is nutritional deficiency disease.